Dr. Richard Idro makes his presentation at the National Dissemination and Policy Dialogue on Post Discharge Malaria Chemoprevention, 3rd December 2020, Golden Tulip Hotel, Kampala Uganda.
“Malaria is a terrible disease. It affects you beyond discharge. Once treated for malaria, you are susceptible to more infections, and the chances for re-admission are very high.”
Uganda’s fight against malaria has received a boost after medical researchers recommended that a wonder drug that has produced positive results in Uganda, Kenya and Malawi be embraced globally.
Results of the study showed that treatment with Dihydroartemisinin–Piperaquine (DP) should now be the preferred treatment for malaria in both children and adults after discharge. The trials in children indicated reduced number of deaths from severe malaria by 80 per cent.
The study-the Malaria Chemoprevention in the Postdischarge management of severe Anemia was carried out over a two-year period at Jinja, Kamuli, Hoima, Masaka and Mubende Regional Referral hospitals and studied 1,049 children with severe malaria, which kills nearly a million people each year, mainly young children and pregnant women.
Dr. Robert Opoka, a Senior Lecturer at the Department of Paediatrics and Children Health, College of Health Sciences, Makerere University
“We focused on those hospitals because those are the areas that are most hit with Malaria.We found out that Children who have been hospitalized with severe anemia in areas of Africa in which Malaria is endemic have a high risk of readmission and death within 6 months after discharge,” said Dr. Robert Opoka, a Senior Lecturer at the Department of Paediatrics and Children Health, Makerere University College of Health Science.
Dr. Opoka noted that they allocated children with severe malaria with antimalarial during the first 3months post-discharge at 2,6 and 10 weeks and they were followed for three months and found out that 80 percent of the children on the antimalarial survived.
“It was observed that there was 70% significant reduction in either deaths or re-admissions among the children receiving the antimalarials compared to the group of children who were not on admission,” Dr. Opoka noted.
Dr. Richard Idro, Senior Lecturer, College of Health Sciences, Makerere University
The study, whose findings have been published in the latest edition of the New England Journal of Medicine (NEJM), was funded by the Norwegian Research Council. It involved an international consortium of researchers. Some of the members of the research team from Makerere University College of Health Sciences included: Dr. Richard Idro, Dr. Aggrey Dhabangi and Dr. Robert Opoka
Malaria is caused by parasites that are injected into the bloodstream by infected mosquitoes. Severe malaria is often the main reason why children are admitted to hospital in sub-Saharan Africa, and one in 10 of these children die.
The Ministry of Health 25th Health Sector Joint Review report 2018/2019 showed that malaria was still the leading cause of admissions for all ages accounting for 32.9 per cent of all admissions.
Dr. Aggrey Dhabangi, Lecturer, College of Health Sciences, Makerere University
“The drug has a huge impact on reducing mortality and morbidity in children under five-years recovering from severe malaria. The children who were not on antimalarials developed respiratory distress, complicated seizures, movement disorders, vision impairment, speech and language impairments, cognitive deficits, epilepsy and destructive behavior,” said Dr. Aggrey Dhabangi, a Lecturer at the Makerere University College of Health Sciences.
Dr. Dhabangi noted that DP is available in both private and public pharmacies. And a dose goes for UGX 3,000 for children and UGX 3,500 for adults and it is supposed to be taken for 3days in a month. “(DP) is a reliably oral effective drug, and it is given to children according to weight and it should be given 14days after discharge and later after a month,” Dhabangi noted.
During the meeting held on 3rd December 2020, Dr. Richard Idro, a Senior Lecturer at the Makerere University College of Health Sciences, revealed that further studies in Malawi have demonstrated that delivery of the drugs using community-based approaches is associated with much higher adherence 24% than hospital-based approaches.
Dr. Charles Olaro, Director of Curative Services, Ministry of Health
“These children are readmitted or die because by the time they are discharged from the hospital they have not fully recovered so when they go back home especially to places with high infections, they get attacked again, but with the antimalarial they get protected until they recover and gain their immunity,” Dr. Idro noted. The researchers recommended that after discharge, the children should be given Multi-Vitamin supplementation and use mosquito nets.
Responding to the findings, Dr. Charles Olaro, the Director of Curative Services at the Ministry of Health, said that he was happy with the research findings and promised to translate the research findings into policy so that Children in Uganda are saved.
“Malaria is still one of the diseases burdening clinical services, so we still need more research and innovations in that area. We need to start up a package where health workers do not only stop at discharging patients but also educate them about the post discharge,” Dr. Olaro, noted. He assured the public that the Ministry of Health had stocked enough Dihydroartemisinin-Piperaquine (DP) for public hospitals.
The Vice Chancellor of Makerere University, Prof. Barnabas Nawangwe who was represented by Dr. Sabrina Kitaka from the College of Health Sciences commended the research team comprising Makerere University researchers for creating a paradigm shift that focuses on only treatment of malaria to a preventive approach that will save lives. The Vice Chancellor expressed Makerere University’s readiness to review the curricula to include prevention of malaria and chemo prevention in the management of malaria. Noting that the researchers focused on three (3) months after discharge, he appealed to research team to consider an option of extending the period of follow up to six (6) months so that more lives are saved.
Dr. Jimmy Opigo, Assistant Commissioner-Health Services, National Malaria Control Division (NMCD), Ministry of Health
Dr. Jimmy Opigo, the Assistant Commissioner-Health Services at the National Malaria Control Division said: “We are happy that this PMC study has enabled people to realise that treatment of malaria and discharge is not enough. There is need for longitudinal management of those discharged. The medical team and health care workers should add patient education and improve health care practices in the management of malaria.”
The Makerere University College of Health Sciences and Case Western Reserve University, partnering with Mbarara University of Science and Technology, are implementing a five-year project titled “Self-management Intervention for Reducing Epilepsy Burden Among Adult Ugandans with Epilepsy.”
The program is funded by the National Institute of Health (NIH) and the National Institute of Neurological Disorders and Stroke (NINDS). One aspect of the program is to provide advanced degree training to qualified candidates interested in pursuing clinical and research careers in Epilepsy. We aim to grow epilepsy research capacity, including self-management approaches, in SSA.
The Project is soliciting applications for Master’s Research thesis support focusing on epilepsy-related research at Makerere University and Mbarara University, cohort 3, 2026/2027.
Selection criteria
Should be a Master’s student of the following courses: MMED in Internal Medicine, Paediatrics, Surgery and Neurosurgery, Psychiatry, Family Medicine, Public Health, Master of Health Services Research, MSc. Clinical Epidemiology and Biostatistics, Nursing, or a Master’s in the Basic Sciences (Physiology, Anatomy, Biochemistry, or any other related field).
Should have completed at least one year of their Master’s training in the courses listed above.
Demonstrated interest in Epilepsy and Neurological diseases, care and prevention, and commitment to develop and maintain a productive career, and devoted to Epilepsy, Clinical Practice, and Prevention.
Research Programs:
The following are the broad Epilepsy research priority areas (THEMES), and applicants are encouraged to develop research concepts in the areas of: Applicants are not limited to these themes; they can propose other areas.
The epidemiology of Epilepsy and associated risk factors.
Determining the factors affecting the quality of life, risk factors, and outcomes (mortality, morbidity) for Epilepsy, epilepsy genetics, and preventive measures among adults.
Epilepsy in childhood and its associated factors, preventative measures etc.
Epilepsy epidemiology and other Epilepsy related topics.
Epilepsy interventions and rehabilitation
In addition to a formal master’s program, trainees will receive training in bio-ethics, Good Clinical Practice, behavioral sciences research, data and statistical analysis, and research management.
The review criteria for applicants will be as follows:
· Relevance to program objectives
Quality of research and research project approach
Feasibility of study
Mentors and mentoring plan; in your mentoring plan, please include who the mentors are, what training they will provide, and how often they propose to meet with the candidate.
Ethics and human subjects’ protection.
Application Process
Applicants should submit an application letter accompanied by a detailed curriculum vitae, two recommendation letters from Professional referees or mentors, and a 2-page concept or an approved full proposal describing your project and addressing Self-Management Intervention for Reducing Epilepsy Burden Among Adults or an epilepsy-related problem.
For more information, inquiries, and additional advice on developing concepts, don’t hesitate to get in touch with the following:
Ms. Josephine N Najjuma: najjumajosephine@yahoo.co.uk
Only short-listed candidates will be contacted for Interviews.
A soft copy should be submitted to the Administrator of the Epilepsy Project. Email: smireb2@gmail.com; Closing date for the Receipt of applications is 5th July 2026.
Prof. Peter Waiswa was among key experts who featured at the World Health Regional Summit in Kenya. The high-level meeting ran under the theme Reimagining Africa’s Health Systems, bringing together researchers, policymakers, and health leaders to discuss how the continent can build resilient and equitable health systems in the face of climate and environmental shocks.
Prof. Waiswa participated in a panel discussion under the sub-theme Women, Adolescents, Child Health and Nutrition, which took place on Wednesday, 29 April 2026, from 09:30 to 11:00 EAT in Room CR3.
The session, chaired by Dr. Malachi Ochieng Arunda, focused on the growing intersection between environment, climate change, and health outcomes for mothers, adolescents, and children.
During the panel, Prof. Waiswa highlighted the urgent need to integrate climate adaptation into maternal and child health programming. He noted that rising temperatures, food insecurity, and extreme weather events are already disrupting health services and worsening nutrition outcomes across Africa. The discussion emphasized practical solutions, including strengthening primary healthcare, protecting vulnerable groups, and promoting cross-sector partnerships.
Makerere University School of Public Health invites applications for the 2026 intake of the Certificate in Applied Health Systems Research, a short, intensive virtual programme designed for professionals working at the intersection of research, policy, and health system practice.
Why this course matters
Health system challenges are rarely linear. They are shaped by institutional complexity, political realities, and competing stakeholder interests. In many cases, the issue is not the absence of evidence, but the difficulty of producing research that is relevant, timely, and usable within real decision-making environments. This course is designed to address that gap, equipping participants to generate and apply evidence that responds to actual system constraints.
frame research problems grounded in real system conditions
analyse complex interactions within health systems
design policy-relevant and methodologically sound studies
translate findings into actionable insights for decision-making
Course format and key details
The programme runs virtually from 6th to 17th July 2026 (2:00–5:45 PM EAT) and combines interactive sessions, applied learning, and expert-led discussions across: